Researchers make key malarial drug-resistence finding
Friday, 17 April 2015
According to the World Health Organization's 2014 World Malaria Report, there are an estimated 198 million cases of malaria worldwide with 3.3 billion people at risk for contracting the infection. Although the impact of malaria is still significant, the statistics reflect a considerable reduction in the global malaria burden.
Certain genes might make some people more prone to experience the placebo effect
Wednesday, 15 April 2015
Researchers are beginning to explore whether the genetics of patients who experience a placebo effect are different from those of patients who don't. It's well known that people can feel better if they believe they are receiving treatment, but the biological pathways involved are relatively unexplored.
New WHO statement on public reporting of clinical trial results announced
Tuesday, 14 April 2015
The World Health Organization (WHO) have announced a new statement on the public disclosure of clinical trial results which updates and expands a previous statement that noted the "the registration of all interventional trials is a scientific, ethical, and moral responsibility." The new statement includes timelines by which researchers are expected to report clinical trials results.
UTMB researchers develop Ebola vaccine effective in a single dose
Wednesday, 08 April 2015
An interdisciplinary team from The University of Texas Medical Branch at Galveston and Profectus BioSciences, Inc. has developed a quick-acting vaccine that is both safe and effective with a single dose against the Ebola strain that killed thousands of people in West Africa last year.
Bayer Grants4Apps® Accelerator: Submissions Open for Digital Health Startups
Tuesday, 07 April 2015
The Grants4Apps® Accelerator is a mentoring program for digital health startups taking place in Berlin. This year's batch with five startups runs from August 10th until December 4th, 2015. The program offers mentoring by entrepreneurs and Bayer experts, office space for 100 days at Bayer HealthCare Pharmaceuticals headquarters, and funding of 50,000€.
Researchers question use of paracetamol for lower back pain and osteoarthritis
Wednesday, 01 April 2015
New research shows that paracetamol is ineffective in reducing pain, disability or improving quality of life for patients who suffer from low back pain or osteoarthritis of the hip or knee, and its use may affect the liver. The study published in the British Medical Journal provides new evidence that paracetamol is no better at treating low back pain than a placebo and its effect on osteoarthritis of the hip or knee is too small to be clinically worthwhile.
The average living cell needs communication skills: It must transmit a constant stream of messages quickly and efficiently from its outer walls to the inner nucleus, where most of the day-to-day decisions are made. But this rapid, long-distance communication system leaves itself open to mutations that can give rise to a "spam attack" that promotes cancer.